3,511 results found

On November 16, 2017, the Government of Alberta introduced Bill 26, An Act to Control and Regulate Cannabis (Bill), which contains the proposed regulatory framework for recreational cannabis sales in Alberta.

The recent developments in Canadian cannabis policy and legislation have sparked significant investment in licensed cannabis producers.

At its July 8, 2024 meeting, the Ontario College of Pharmacists Board of Directors ("OCP") followed through with its commitment made on March of 2024...

This month, the British Columbia Health Minister announced plans to introduce legislation that will increase the BC's provincial tax on vaping products from 7% to 20%.

On February 5, 2018, the British Columbia government supplied additional insight into its proposed retail and wholesale distribution framework for non-medical cannabis ...

More stringent drug-monitoring measures may be on the horizon for all drugs and medical devices other than natural health products.

Amgen recently started litigation against Teva over the biologic drug filgrastim (Court File No. T-989-12).

Brand names can play a key part of the management of a product over its life cycle.

This proceeding brought by Bristol-Myers Squibb Canada Co. and Merck Sharpe & Dohme Corp. under the "Patented Medicines (Notice of Compliance) Regulations" dealt with two patents.

In October 2018, the Canadian Agency for Drugs and Technologies in Health (CADTH) issued an interesting Environmental Scan on International Policies on the Appropriate Use of Biosimilar Drugs (Report).

The Human Rights Tribunal of Alberta recently determined that an employer did not discriminate against a job candidate by revoking an offer of employment after the job candidate failed a pre-employment drug test.

On March 25, 2025, Canada's Drug Agency published its annual Watch List, which identifies technologies with the most potential to transform health systems and shape the future of health care in Canada.

Provincial and territorial premiers first announced the Pan-Canadian Pricing Alliance (PCPA), an initiative aimed at facilitating multi-jurisdictional negotiations on prices of brand name drugs, back in the summer of 2010.

As of February 11, 2022, the retention period for records of clinical trials of drugs and natural health products has been reduced from 25 years to 15 years in Canada.

Itching for news on the Safe Food for Canadians Act? You're in luck: the Canadian Food Inspection Agency just released its "What We Heard Report", which summarizes the feedback the CFIA received ...

Earlier this month, the NDP and the Liberals announced a deal to introduce the first piece of a national pharmacare program providing federal funding for medications for Canadians.

On November 12, 2019, the Canadian Securities Administrators issued Multilateral Staff Notice 51-359 — Corporate Governance Related Disclosure Expectations...